Immatics N.V. $IMTX Holdings Decreased by Sectoral Asset Management Inc.

Sectoral Asset Management Inc. reduced its stake in shares of Immatics N.V. (NASDAQ:IMTX) by 88.8% during the fourth quarter, Holdings Channel.com reports. The firm owned 63,015 shares of the company’s stock after selling 497,479 shares during the period. Sectoral Asset Management Inc.’s holdings in Immatics were worth $662,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Bank of America Corp DE raised its stake in shares of Immatics by 166.0% during the fourth quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock valued at $25,000 after purchasing an additional 2,231 shares in the last quarter. Vanguard Personalized Indexing Management LLC raised its stake in shares of Immatics by 8.3% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 47,635 shares of the company’s stock valued at $406,000 after purchasing an additional 3,666 shares in the last quarter. Insigneo Advisory Services LLC bought a new stake in shares of Immatics during the third quarter valued at about $103,000. Engineers Gate Manager LP bought a new stake in shares of Immatics during the second quarter valued at about $124,000. Finally, BNP Paribas Financial Markets raised its stake in shares of Immatics by 105.2% during the second quarter. BNP Paribas Financial Markets now owns 78,123 shares of the company’s stock valued at $420,000 after purchasing an additional 40,058 shares in the last quarter. 64.41% of the stock is currently owned by institutional investors.

Immatics Stock Performance

Shares of NASDAQ IMTX opened at $11.62 on Monday. Immatics N.V. has a twelve month low of $4.93 and a twelve month high of $12.41. The company has a market capitalization of $1.56 billion, a price-to-earnings ratio of -5.84 and a beta of 1.31. The firm has a 50-day moving average of $10.58 and a two-hundred day moving average of $10.19.

Immatics (NASDAQ:IMTX) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.08). Immatics had a negative net margin of 572.35% and a negative return on equity of 47.36%. The business had revenue of $8.81 million during the quarter, compared to analyst estimates of $9.79 million. As a group, research analysts predict that Immatics N.V. will post -1.75 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. TD Cowen assumed coverage on shares of Immatics in a research note on Tuesday, April 28th. They set a “buy” rating on the stock. Mizuho set a $25.00 price objective on shares of Immatics in a research note on Thursday, February 19th. Wall Street Zen cut shares of Immatics from a “hold” rating to a “sell” rating in a research note on Saturday, May 2nd. Jefferies Financial Group began coverage on shares of Immatics in a research note on Monday, March 16th. They set a “buy” rating and a $18.00 price objective on the stock. Finally, Chardan Capital reissued a “buy” rating and issued a $25.00 price target on shares of Immatics in a report on Tuesday, May 19th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.00.

Immatics Company Profile

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.